Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 | Zendy

Roy S. Herbst | Zendy; Giuseppe Giaccone | Zendy; Joan H. Schiller | Zendy; Ronald B. Natale | Zendy; Vincent A. Miller | Zendy; Christian Manegold | Zendy; Giorgio V. Scagliotti | Zendy; Rafael Rosell | Zendy; Ira A. Oliff | Zendy; James A. Reeves | Zendy; Michael Wolf | Zendy; Annetta Krebs | Zendy; Steven D. Averbuch | Zendy; Judith Ochs | Zendy; John Grous | Zendy; Abderrahim Fandi | Zendy; David H. Johnson | Zendy

Open Access

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Author(s) -

Roy S. Herbst,

Giuseppe Giaccone,

Joan H. Schiller,

Ronald B. Natale,

Vincent A. Miller,

Christian Manegold,

Giorgio V. Scagliotti,

Rafael Rosell,

Ira A. Oliff,

James A. Reeves,

Michael Wolf,

Annetta Krebs,

Steven D. Averbuch,

Judith Ochs,

John Grous,

Abderrahim Fandi,

David H. Johnson

Publication year - 2004

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2004.07.215

Subject(s) - gefitinib , medicine , tolerability , carboplatin , lung cancer , placebo , oncology , chemotherapy , paclitaxel , docetaxel , phases of clinical research , pharmacology , epidermal growth factor receptor , cancer , adverse effect , pathology , cisplatin , alternative medicine

Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance antitumor efficacy of cytotoxics, and combination with paclitaxel and carboplatin had acceptable tolerability in a phase I trial. Gefitinib monotherapy demonstrated unparalleled antitumor activity for a biologic agent, with less toxicity than docetaxel, in phase II trials in refractory, advanced non-small-cell lung cancer (NSCLC). This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research